Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab bridging ASCT in R/R DLBCL
NCT06682130Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Complete Remission Rate. Started Nov 2024; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06682130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682130.